FOSUN HEALTH Logo

Cervical Cancer Treatment

catalogue

Cervical Cancer Treatment

Cervical Cancer Treatment

No other gynaecological cancer offers a treatment menu this wide — from a cone biopsy that ends the matter in an afternoon to chemoradiotherapy that replaces surgery entirely. The stage decides the route, and within the early stages, the wish to preserve fertility can shape it further.

The route at each stage

Cervical cancer treatment is unusual in that the main fork is not between drug A and drug B but between an operation and radiotherapy — and which of the two applies depends on findings the MRI measures before anything starts:

  • Stage IA1 — cone biopsy alone in most cases; hysterectomy is reserved for situations where conization is incomplete or childbearing is finished and margins cannot be cleared.
  • Stage IB1–IB2 — radical hysterectomy with pelvic node assessment, or radical trachelectomy at 2 cm or less where fertility is to be kept.
  • Stage IB3–IIB — definitive chemoradiotherapy: radiotherapy five days a week with weekly cisplatin, completed by brachytherapy. Surgery is generally replaced here because the tumour has reached the parametrium or exceeded 4 cm.
  • Stage IIIC — chemoradiotherapy with an extended field covering the involved nodes; surgical staging of the nodes may precede it in selected cases.
  • Stage IVA–IVB — systemic treatment as the mainstay, with radiotherapy added to control bleeding, pain or obstruction.

Where surgery is chosen and nodes turn out to be involved, the plan often converts to chemoradiotherapy afterwards — adjuvant treatment based on what the pathology showed. That conversion is not a failure of the operation but information it produced, and it is one reason nodal assessment is part of every radical procedure.

Cone biopsy (LEEP and cold knife)

For microscopic disease, the cone is the treatment. A LEEP loop or a scalpel removes a measured cylinder of cervical tissue with the lesion inside it, and the specimen is measured for depth of invasion and margin status. When invasion is no deeper than 3 mm and margins are clear, conization is complete treatment — the uterus, and with it future fertility, stay intact.

The procedure is a day-case, and its trade-offs are practical: a slightly shortened cervix, which is monitored in any later pregnancy, and a small risk of recurrence that follow-up smears and HPV testing cover. What conization cannot do is treat tumour that has grown beyond what it removes — which is why the depth measurement matters and why an incomplete or unmeasurable cone leads to further surgery rather than reassurance.

Radical hysterectomy

Radical hysterectomy for cervical cancer is not the hysterectomy done for fibroids. It removes the uterus, the cervix, the upper vagina and — the defining part — the parametrium, the tissue beside the cervix through which the disease spreads first, together with the pelvic lymph nodes or a sentinel node assessment. Removing the parametrium is what makes the operation radical, and it is also what makes nerve preservation a skill: the autonomic nerves running through this tissue carry bladder and bowel function.

The operation is done by open or minimally invasive approach, and the choice is a genuine discussion — the evidence on minimally invasive radical hysterectomy remains debated, and centres that offer laparoscopy do so with defined techniques and candid counselling. What matters for the outcome is the completeness of the parametrial and nodal removal at a centre doing the operation regularly, which is why volume is the question to ask.

Radical trachelectomy: keeping fertility

For tumours of 2 cm or less, and in selected cases up to 4 cm, radical trachelectomy removes the cervix, the parametrium and the upper vagina while leaving the body of the uterus in place, joined to the vagina by a permanent stitch (a cerclage) that carries later pregnancies. It removes the same radical territory as a radical hysterectomy — nodes included — except for the uterus itself.

The prerequisites are precise: tumour size measured on MRI, no parametrial or nodal involvement, and a pathology type that does not argue against it (certain aggressive histologies are excluded). Pregnancies after trachelectomy are well documented, though delivery is by caesarean and the cerclage is permanent. The procedure exists because fertility decisions come before treatment in this cancer — a point covered further below.

Chemoradiotherapy and brachytherapy

For locally advanced disease, the standard of care is radiotherapy five days a week with weekly cisplatin, over roughly five weeks, completed by brachytherapy — radioactive source applications placed inside the cervix and vagina, planned on MRI, that deliver a concentrated dose to the tumour while sparing bladder and bowel. The chemotherapy sensitises the tumour to the radiotherapy; the brachytherapy is what lets the total dose reach curative levels.

Brachytherapy deserves emphasis, because it is the component most easily missed in planning made far from a treating centre: locally advanced disease treated with external radiotherapy alone is not the same treatment. Centres that perform applications routinely plan them with MRI guidance, and the schedule — external field, then the applications — is one integrated course. Side effects during the course are manageable and known; the follow-up after it is structured and long, which is also how recurrence, if it happens, is caught early.

Drug treatment for advanced disease

Where disease has spread beyond what surgery and radiotherapy cover, treatment is systemic, and the current logic rests on three layers:

  • Immunotherapy first-line — pembrolizumab added to chemotherapy, with or without bevacizumab, where the tumour expresses PD-L1 (a combined positive score of 1 or more). Testing the biopsy for PD-L1 at diagnosis is what keeps this door open.
  • Antibody–drug conjugates in later lines — tisotumab vedotin for disease that has progressed after prior treatment, delivering a drug payload directly to tumour cells.
  • Palliative radiotherapy and procedures — targeted radiotherapy to control bleeding or pain, and stenting where tumour obstructs the ureter or bowel. These are comfort treatments and are planned alongside, not after, systemic therapy.

What decides eligibility is the pathology and its markers rather than age or general fitness assumptions: PD-L1, mismatch repair status and TMB should be on the original report, which is why the diagnosis section stresses requesting them at the time of biopsy.

Fertility decisions before treatment

This is the cancer where fertility must be discussed before the first treatment, because the treatments themselves end it: hysterectomy removes the uterus, and radiotherapy permanently stops ovarian function within the treated field. Egg or embryo freezing does not restore the possibility of carrying a pregnancy after either of those — so for a woman who wants children, the treatment choice itself is the fertility decision.

The pathways that preserve fertility are defined: conization for microscopic disease, radical trachelectomy for tumours of 2 cm or less, and — where only ovaries are at risk from a lower field — options such as ovarian transposition discussed with the radiotherapy team before planning. Each has eligibility criteria measured on the staging MRI, which is one more reason the MRI belongs before the first procedure rather than after it.

How the MDT decides

A cervical cancer MDT puts four documents on the table — pathology, MRI, nodal imaging and the FIGO stage — and answers three questions in order. First: is fertility to be preserved? Second: is this an operation or chemoradiotherapy? — decided by tumour size, parametrial status and nodes. Third: is the tissue tested for PD-L1? — because that answer, filed at diagnosis, is what keeps immunotherapy available if disease recurs or advances later.

The sequence matters because steps cannot be reordered: a hysterectomy performed before the MRI question is answered cannot be revised, and radiotherapy planned without nodal imaging misses what it should cover. For international patients this translates into one instruction — send the complete file before any irreversible step, and a written MDT assessment returns within 48 hours of it being complete.

Frequently Asked Questions

Can early cervical cancer be treated without removing the uterus?

Yes, at defined stages. Microscopic IA1 disease is treated by cone biopsy alone, leaving the uterus intact. For tumours of 2 cm or less, radical trachelectomy removes the cervix and parametrium while keeping the body of the uterus, with pregnancies afterwards delivered by caesarean. Both routes have strict eligibility criteria based on the measured size, depth and nodal status — which is why the staging MRI precedes any decision.

Why does locally advanced disease skip surgery?

Because at that stage radiotherapy does more than an operation can. Tumour that has reached the parametrium or the pelvic nodes would require removing tissue central to bladder and bowel function, and even then incompletely. Concurrent chemoradiotherapy with brachytherapy treats the tumour, the parametrium and the nodes as one continuous field — the standard of care at stage IB3 and above.

What is brachytherapy and can it be skipped?

It is internal radiotherapy: radioactive sources placed briefly inside the cervix and vagina, planned on MRI, delivering a concentrated dose to the tumour that external beams cannot match without harming the bladder and bowel. It is what makes chemoradiotherapy complete and curative for locally advanced disease, and it is not optional — treatment without it is a different, less complete course. This is the component to confirm exists at any treating centre.

What are the treatment options if the cancer comes back?

They depend on where it is and whether it was previously irradiated. Recurrence at the centre after surgery alone can sometimes be treated with radiotherapy or, in selected cases, with a further radical operation. Recurrence after prior radiotherapy is treated systemically — pembrolizumab where PD-L1 is positive, chemotherapy, and antibody–drug conjugates such as tisotumab vedotin in later lines. The PD-L1 result filed at diagnosis is what opens the immunotherapy route here.

Deciding between surgery, chemoradiotherapy and fertility-sparing options?

Choosing between surgery and chemoradiotherapy is a staging decision, not a preference. Upload the pathology and staging MRI, and our gynaecological oncology MDT will state the appropriate route and whether fertility-sparing options apply — in writing, within 48 hours.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*